MYMD vs. FREQ, CDIO, TRIB, BMRA, VRAX, NAVB, OCX, ICCC, DRRX, and ALGS
Should you be buying MyMD Pharmaceuticals stock or one of its competitors? The main competitors of MyMD Pharmaceuticals include Frequency Therapeutics (FREQ), Cardio Diagnostics (CDIO), Trinity Biotech (TRIB), Biomerica (BMRA), Virax Biolabs Group (VRAX), Navidea Biopharmaceuticals (NAVB), OncoCyte (OCX), ImmuCell (ICCC), DURECT (DRRX), and Aligos Therapeutics (ALGS). These companies are all part of the "medical" sector.
MyMD Pharmaceuticals (NASDAQ:MYMD) and Frequency Therapeutics (NASDAQ:FREQ) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, community ranking, dividends, risk, analyst recommendations and institutional ownership.
Frequency Therapeutics received 59 more outperform votes than MyMD Pharmaceuticals when rated by MarketBeat users.
MyMD Pharmaceuticals has higher earnings, but lower revenue than Frequency Therapeutics.
In the previous week, Frequency Therapeutics had 3 more articles in the media than MyMD Pharmaceuticals. MarketBeat recorded 5 mentions for Frequency Therapeutics and 2 mentions for MyMD Pharmaceuticals. MyMD Pharmaceuticals' average media sentiment score of 1.44 beat Frequency Therapeutics' score of 0.00 indicating that MyMD Pharmaceuticals is being referred to more favorably in the media.
MyMD Pharmaceuticals has a beta of 2.17, meaning that its stock price is 117% more volatile than the S&P 500. Comparatively, Frequency Therapeutics has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500.
9.6% of MyMD Pharmaceuticals shares are held by institutional investors. Comparatively, 13.2% of Frequency Therapeutics shares are held by institutional investors. 2.6% of MyMD Pharmaceuticals shares are held by insiders. Comparatively, 16.8% of Frequency Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Frequency Therapeutics' return on equity of -107.67% beat MyMD Pharmaceuticals' return on equity.
Summary
Frequency Therapeutics beats MyMD Pharmaceuticals on 7 of the 10 factors compared between the two stocks.
Get MyMD Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for MYMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MYMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MyMD Pharmaceuticals Competitors List
Related Companies and Tools
